Multistakeholder article highlights the need for genomic correlates and outcome data for belzutifan efficacy in advanced pheochromocytoma and paraganglioma.
The HIF-2α inhibitor belzutifan was recently U.S. Food and Drug Administration (FDA)-approved for advanced pheochromocytoma/paraganglioma. This multistakeholder article calls for clinical-trial genomic correlates and outcome data to clarify efficacy across these molecularly heterogeneous neuroendocrine tumors.
No takes yet. Share an insight, caveat, or question.
Toledo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: